查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症幹細胞的全球市場:市場規模 - 各癌症，各作用機制，各移植，各用途，各終端用戶，各地區展望，競爭策略，各市場區隔預測(～2032年)
市場調查報告書
商品編碼
1170429

癌症幹細胞的全球市場:市場規模 - 各癌症，各作用機制，各移植，各用途，各終端用戶，各地區展望，競爭策略，各市場區隔預測(～2032年)

Cancer Stem Cells Market Size- By Cancer, By Mode Of Action, By Transplantation, By Application, By End User- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 226 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球癌症幹細胞的市場規模，預計至2032年達到26億8,000萬美元，以10.29％的年複合成長率成長。

市場擴大的主要原因，是全球癌症罹患率的上升。改變人類DNA的基因工程學，和從幹細胞做出三次元結構的組織的類器官技術的出現，在COVID-19間的幹細胞研究中大幅發展的2個要素，對全球癌症幹細胞市場帶來了好影響。

本報告提供全球癌症幹細胞市場相關調查，市場動態，市場變數與展望，各癌症、作用機制、移植、用途、最終用途、地區的市場分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，及課題分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球癌症幹細胞市場上COVID-19的影響

第5章 市場變數與展望

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球癌症幹細胞市場:各癌症(2019年～2032年(100萬美元))

  • 急性白血病
  • 再生不良性貧血
  • 慢性淋巴性白血病
  • 骨質疏鬆症

第7章 全球癌症幹細胞市場:各作用機制(2019年～2032年(100萬美元))

  • 作為標的癌症幹細胞
    • 各抗CSC治療藥物
    • 產品
  • 幹細胞為基礎的癌症治療
    • 自體SC移植
    • 同類SC移植

第8章 全球癌症幹細胞市場:各移植(2019年～2032年(100萬美元))

  • 異體幹細胞治療
  • 自體幹細胞治療

第9章 全球癌症幹細胞市場:各用途(2019年～2032年(100萬美元))

  • 血液癌症
  • 乳癌
  • 子宮頸癌症
  • 大腸癌症
  • 肺癌症
  • 前列腺癌症

第10章 全球癌症幹細胞市場:各最終用途(2019年～2032年(100萬美元))

  • 細胞庫、組織銀行
  • 醫院、手術用檢驗室
  • 製藥企業、生物醫學企業

第11章 全球癌症幹細胞市場:各地區(2019年～2032年(100萬美元))

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲

第12章 企業簡介

  • AbbVie Inc.
    • 企業概要
    • 財務展望
    • 產品概要
    • 最近的開發
  • Advanced Cell Diagnostics Inc.
  • Bionomic
  • BioNTech
  • BioTime Inc.
  • Caladrius Biosciences Inc.
  • Celgene Corp.
  • ExCellThera
  • Gamida Cell
  • Irvine Scientific
  • Lonza
  • MacroGenics Inc.
  • Menarini Group
  • Merck KGaA
  • Mereo BioPharma
  • Miltenyi Biotec
  • PromoCell GmbH
  • Propanc Biopharma
  • Silicon Biosystems
  • Sino Biological Inc.
  • Thermo Fisher Scientific Inc.
  • VIaCyte Inc.
簡介目錄
Product Code: HLCA2220

Global Cancer Stem Cells Market Overview:

According to SPER Market Research, the Global Cancer Stem Cells Market is estimated to reach USD 2.68 billion by 2032 with a CAGR of 10.29%.

The tumour's other cell types are produced by the cancer cell, which has the capacity to divide and grow continuously. Cancer stem cells are believed to oversee tumour development, metastasis, and recurrence. These are the rare forms of godlike cells called cancer stem cells are found in tumours and give rise to a wide range of cell types that make up the tumour. These cells have been identified in several human tumours and may serve as targets for cancer therapy. Most anti-cancer medications function by inducing the death of cancer cells. Even though these treatments seem to be working, some individuals nonetheless have a disease recurrence. The primary driver fuelling the expansion of the cancer stem cell market is the rising incidence of cancer in the world.

Impact of COVID-19 on the Global Cancer Stem Cells Market:

The cancer stem cell sector has prospered from the COVID-19 epidemic. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from originating stem cells, are two of the most significant strides in stem cell research during COVID-19. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from stem cells, have been two of the most important strides in stem cell research during COVID-19. This element had a favourable effect on the world market for cancer stem cells. Additionally, there has been an increase in the use of allogeneic stem cell therapy and hematopoietic cell transplantation (HCT), particularly among cancer patients who have COVID-19 infections.

Scope of the Report:

Report Metric Details:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Cancer, By Mode Of Action, By Transplantation, By Application, By End User
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: AbbVie Inc., Advanced Cell Diagnostics Inc., Bionomics, BioNTech, BioTime Inc., Caladrius Biosciences Inc., Celgene Corp., ExCellThera, Gamida Cell, Irvine Scientific, Lonza, MacroGenics, Inc., Menarini Group, Merck KGaA, Mereo BioPharma, Miltenyi, Biotec, PromoCell GmbH, Propanc Biopharma, Silicon Biosystems, Sino Biological Inc., Thermo Fisher Scientific Inc., ViaCyte Inc.

Global Cancer Stem Cells Market Segmentation:

  • By Caner: Based on the Caner, Global Cancer Stem Cells Market is segmented as; Acute Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Osteopetrosis.
  • By Mode Of Action: Based on the Mode Of Action, Global Cancer Stem Cells Market is segmented as; Targeted Cancerous Stem Cells {By Anti-CSC Therapeutics (Pathway Inhibitors, Surface Marker Based, Immuno-evasion and Targeting Tumour Microenvironment, Nanoparticle-based Therapies), Products (Cell-Culturing, Cell-Separation, Cell-Analysis, Molecular Analysis)}, Stem Cell Based Cancer Therapy (Autologous SC Transplant, Allogeneic SC Transplant).
  • By Transplantation: Based on the Transplantation, Global Cancer Stem Cells Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
  • By Application: Based on the Application, Global Cancer Stem Cells Market is segmented as; Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer.
  • By End User: Based on the End Use, Global Cancer Stem Cells Market is segmented as; Hospitals and surgical laboratories, Cell banks and tissue banks, Pharmaceutical and biomedical companies.
  • By Region: Due to improvements in healthcare infrastructure and strong reimbursement policies across the region, North America had the substantial share, accounting for more than two-fifths of the worldwide cancer stem cell market. On the other hand, the Asia-Pacific area will have the fastest growth in the following years. This is because the governments of China, Japan, and India are developing regulations for the development of stem cell research facilities and investing in healthcare infrastructure.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity, and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Cancer Stem Cells Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Cancer Stem Cells Market, By Cancer, 2019-2032 (USD Million)

  • 6.1. Acute Leukemia
  • 6.2. Aplastic Anemia
  • 6.3. Chronic Lymphocytic Leukemia
  • 6.4. Osteopetrosis

7. Global Cancer Stem Cells Market, By Mode Of Action, 2019-2032 (USD Million)

  • 7.1 Targeted Cancerous Stem Cells
    • 7.1.1 By Anti-CSC Therapeutics
      • 7.1.1.1 Pathway Inhibitors
      • 7.1.1.2 Surface Marker Based
      • 7.1.1.3 Immuno-evasion and Targeting Tumour Microenvironment
      • 7.1.1.4 Nanoparticle-based Therapies
    • 7.1.2 Products
      • 7.1.2.1 Cell-Culturing
      • 7.1.2.2 Cell-Separation
      • 7.1.2.3 Cell-Analysis
      • 7.1.2.4 Molecular Analysis
  • 7.2 Stem Cell Based Cancer Therapy
    • 7.2.1 Autologous SC Transplant
    • 7.2.2 Allogeneic SC Transplant

8. Global Cancer Stem Cells Market, By Transplantation, 2019-2032 (USD Million)

  • 8.1. Allogeneic Stem Cell Therapy
  • 8.2. Autologous Stem Cell Therapy

9. Global Cancer Stem Cells Market, By Application, 2019-2032 (USD Million)

  • 9.1. Blood Cancer
  • 9.2. Breast Cancer
  • 9.3. Cervical Cancer
  • 9.4. Colorectal Cancer
  • 9.5. Lung Cancer
  • 9.6. Prostate Cancer

10. Global Cancer Stem Cells Market, By End Use, 2019-2032 (USD Million)

  • 10.1 Cell Banks and Tissue Banks
  • 10.2 Hospital and Surgical Laboratories
  • 10.3 Pharmaceutical and Biomedical Companies

11. Global Cancer Stem Cells Market, By Region, 2019-2032 (USD Million)

  • 11.1 North America
    • 11.1.1. United States
    • 11.1.2. Canada
    • 11.1.3. Mexico
  • 11.2 Europe
    • 11.2.1. Germany
    • 11.2.2. United Kingdom
    • 11.2.3. France
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. India
    • 11.3.4. Australia
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4 South America
    • 11.4.1. Brazil
    • 11.4.2. Argentina
    • 11.4.3. Rest of South America
  • 11.5 Middle East & Africa
    • 11.5.1. Kingdom of Saudi Arabia
    • 11.5.2. United Arab Emirates
    • 11.5.3. Rest of Middle East & Africa

12. Company Profiles

  • 12.1 AbbVie Inc.
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2 Advanced Cell Diagnostics Inc.
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3 Bionomics
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4 BioNTech
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5 BioTime Inc.
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6 Caladrius Biosciences Inc.
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7 Celgene Corp.
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8 ExCellThera
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9 Gamida Cell
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10 Irvine Scientific
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments
  • 12.11 Lonza
    • 12.11.1. Company details
    • 12.11.2. Financial outlook
    • 12.11.3. Product summary
    • 12.11.4. Recent developments
  • 12.12 MacroGenics Inc.
    • 12.12.1. Company details
    • 12.12.2. Financial outlook
    • 12.12.3. Product summary
    • 12.12.4. Recent developments
  • 12.13 Menarini Group
    • 12.13.1. Company details
    • 12.13.2. Financial outlook
    • 12.13.3. Product summary
    • 12.13.4. Recent developments
  • 12.14 Merck KGaA
    • 12.14.1. Company details
    • 12.14.2. Financial outlook
    • 12.14.3. Product summary
    • 12.14.4. Recent developments
  • 12.15 Mereo BioPharma
    • 12.15.1. Company details
    • 12.15.2. Financial outlook
    • 12.15.3. Product summary
    • 12.15.4. Recent developments
  • 12.16 Miltenyi Biotec
    • 12.16.1. Company details
    • 12.16.2. Financial outlook
    • 12.16.3. Product summary
    • 12.16.4. Recent developments
  • 12.17 PromoCell GmbH
    • 12.17.1. Company details
    • 12.17.2. Financial outlook
    • 12.17.3. Product summary
    • 12.17.4. Recent developments
  • 12.18 Propanc Biopharma
    • 12.18.1. Company details
    • 12.18.2. Financial outlook
    • 12.18.3. Product summary
    • 12.18.4. Recent developments
  • 12.19 Silicon Biosystems
    • 12.19.1. Company details
    • 12.19.2. Financial outlook
    • 12.19.3. Product summary
    • 12.19.4. Recent developments
  • 12.20 Sino Biological Inc.
    • 12.20.1. Company details
    • 12.20.2. Financial outlook
    • 12.20.3. Product summary
    • 12.20.4. Recent developments
  • 12.21 Thermo Fisher Scientific Inc.
    • 12.21.1. Company details
    • 12.21.2. Financial outlook
    • 12.21.3. Product summary
    • 12.21.4. Recent developments
  • 12.22 VIaCyte Inc.
    • 12.22.1. Company details
    • 12.22.2. Financial outlook
    • 12.22.3. Product summary
    • 12.22.4. Recent developments